公开(公告)号：US20160194405A1

公开(公告)日：2016-07-07

申请号：US14992519

申请日：2016-01-11

Applicant: Janssen Biotech, Inc.

Inventor： G. Mark Anderson ,  Bernard Scallon ,  Michael Naso ,  Ann Cai ,  Cam Holland

IPC: C07K16/36 ,  A61K31/4164 ,  A61K51/00 ,  A61K47/48 ,  A61K9/00 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/36 ,  A61K9/0019 ,  A61K31/4164 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/00 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.

公开(公告)号：US09708410B2

公开(公告)日：2017-07-18

申请号：US13623144

申请日：2012-09-20

Applicant: Janssen Biotech, Inc.

Inventor： G. Mark Anderson ,  Bernard Scallon ,  Michael Naso ,  Ann Cai ,  Cam Holland

IPC: A61K39/395 ,  C07K16/36 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/36 ,  A61K9/0019 ,  A61K31/4164 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/00 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.